QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE
Qiagen · Decision date Nov 28, 2001
What did the FDA approve?
FDA records P010033 as an original PMA application. The recorded decision is approval, dated Nov 28, 2001.
FDA approval order statement
APPROVAL FOR THE CELLESTIS QUANTIFERON-TB. THE DEVICE IS INDICATED FOR USE AS AN AID IN THE DETECTION OF INFECTION WITH MYCOBACTERIUM TUBERCULOSIS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- Nov 28, 2001
Regulatory record facts
- Identifier
- P010033
- Regulatory pathway
- Premarket approval application
- Applicant
- Qiagen
- Product code
- NCD
- Decision code
- APPR
- Decision date
- Nov 28, 2001
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P010033 received
Application receipt date recorded by FDA.
P010033 · FDA decision
APPR
P010033/S053 · Related supplement
QuantiFERON-TB Gold Plus Test
Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QuantiFERON-TB Gold Plus TestP010033/S053 | Qiagen | PMA supplement | Oct 14, 2026 | FDA |
Explore the linked device profile
Other records with product code NCD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIAISON QuantiFERON-TB Gold Plus II.P180047/S046 | DiaSorin, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| DiaSorin, Inc. | PMA approval | Nov 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Qiagen
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 19300 Germantown Rd., Germantown, MD, 20874
Sources and methodology
- Original FDA record: P010033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

